This Public Sector Bank Revises Interest Rates On FD: Check Latest Rates Here

[ad_1]

Read More/Less


Indian Bank FD Rates For Regular Customers

Regular customers who deposit less than Rs 2 crore will now receive a rate of 2.80 percent to 5.25 percent on deposits maturing in 7 days to 5 years. The following are the most recent interest rates on fixed deposits offered by Indian Bank to the general public, effective from November 5, 2021.

Period Interest rates in % per annum
7 days to 14 days 2.8
15 days to 29 days 2.8
30 days to 45 days 2.8
46 days to 90 days 3.25
91 days to 120 days 3.35
121 days to 180 days 3.5
181 days to less than 9 months 4
9 months to less than 1 year 4.4
1 year 4.95
Above 1 year to less than 2 years 5
2 years to less than 3 years 5.1
3 years to less than 5 years 5.2
5 year 5.25
Above 5 years 5.15
Source: Bank Website. With effect from 05.11.2021

Indian Bank FD Rates For Senior Citizens

Indian Bank FD Rates For Senior Citizens

On their Short Term Deposits, Fixed Deposits, and Money Multiplier Deposit Schemes, senior citizens will continue to get an additional rate of 0.50 percent p.a. for amounts up to ’10 crore for all tenors over the card rate. The latest interest rates on fixed deposits provided by Indian Bank to elderly persons, effective November 5, 2021, are listed below.

Period Interest rates in % per annum
7 days to 14 days 3.3
15 days to 29 days 3.3
30 days to 45 days 3.3
46 days to 90 days 3.75
91 days to 120 days 3.85
121 days to 180 days 4
181 days to less than 9 months 4.5
9 months to less than 1 year 4.9
1 year 5.45
Above 1 year to less than 2 years 5.5
2 years to less than 3 years 5.6
3 years to less than 5 years 5.7
5 year 5.75
Above 5 years 5.65
Source: Bank Website. With effect from 05.11.2021

Indian Bank FD Rates On Deposits of Rs 2 Cr to Rs 5 Cr

Indian Bank FD Rates On Deposits of Rs 2 Cr to Rs 5 Cr

Period Interest rates in % per annum
7 days to 14 days 2.9
15 days to 29 days 2.9
30 days to 45 days 2.9
46 days to 90 days 2.9
91 days to 120 days 2.9
121 days to 180 days 2.9
181 days to less than 9 months 3.25
9 months to less than 1 year 3.25
1 year 3.55
Above 1 year to less than 2 years 3.25
2 years to less than 3 years 3.25
3 years to less than 5 years 3.25
5 year 3.25
Above 5 years 3.25
Source: Bank Website. With effect from 05.11.2021



[ad_2]

CLICK HERE TO APPLY

Global Brokerages See Up To 44% Upside For SBI

[ad_1]

Read More/Less


Planning

oi-Roshni Agarwal

|

The public sector lender has posted robust September numbers better than even street expectations and viewing it several global brokerages have raised its target price. You got it right we here are talking about State Bank of India (SBI).

The firms that have increased price target for SBI stock include Morgan Stanley, Credit Suisse, JPMorgan, and HSBC. After the stock posted its earnings, the stock scaled to a 52-week high price of Rs. 542.2. On losses in the Bank Nifty, SBI stock trades lower by over 2 percent today at Rs. 520.85 per share.

Global Brokerages See Up To 44% Upside For SBI

Global Brokerages See Up To 44% Upside For SBI

Global brokerage Rating Price target
Morgan Stanley Buy Rs. 680
Goldman Sachs Buy Rs.739
CLSA Buy Rs. 750
Macquarie Outperform Rs. 580
Nomura Buy Rs. 650

As per Goldman Sachs, the PSB is well positioned to offer strong profitability over next few years, said the brokerage. On the other hand, CLSA says the company has performed well on most parameters with core margin improving quarter on quarter by 15 bps. RoE has been now at 15 percent with potential upsides.

The asset quality of SBI & large private peers indicate undershooting of credit costs from H2. CLSA increase EPS estimates by 3-5% for FY23-24 & now expect 1% ROA & +15% RoE.

SBI profit during the September quarter jumped 66.7 per cent to Rs 7,626.6 crore as compared to Rs 4,574.2 crore in the same quarter a year-ago period. “The asset quality outcomes are very encouraging to us, while weak credit growth is a concern”, says research firm Macquarie believes that believes the core price to book value is cheap.

PPoP growth will accelerate as growth/rate cycle turns, says Morgan Stanley
The peak in NIM and low net slippages are the key positives, while PPoP trend should correlate with loan growth hereon. FY23F should reflect a normalised RoA & RoE at 0.9% & 16% respectively, says Nomura.

GoodReturns.in

Story first published: Monday, November 8, 2021, 12:43 [IST]



[ad_2]

CLICK HERE TO APPLY

2 Stocks To Buy From Motilal Oswal For Gains Of 21% to 29%

[ad_1]

Read More/Less


Buy State Bank of India

Current market price Rs 523
Target price Rs 675
Gains 29.00%

State Bank of India reported a steady quarter, with net earnings growing 67% YoY to Rs 76.3 billion (15% beat), aided by controlled provisions, as asset quality showed remarkable strength, despite the impact of the second COVID wave.

“It created a family pension provision of Rs 74.2 billion, instead of amortizing it over five years, thus prudently deploying one-off gains from the DHFL recovery and tax refund. The bank has fully provided for its exposure towards the SREI group,” the brokerage has said.

The bank saw NPA/NNPA ratios improving by 42bp/25bp QoQ to 4.9%/1.5% as fresh slippage subsided to Rs 41.8 billion (66bp annualized). Restructured book remained in check at 1.2% of loans, while the SMA pool declined sharply to Rs 66.9 billion (27bp of loans).

State Bank of India: Buy for a price target of Rs 675

State Bank of India: Buy for a price target of Rs 675

State Bank of India has reported a robust performance as it bravely fought off the COVID-19 impact and displayed remarkable resilience in asset quality performance.

“The bank has been reporting continued traction in earnings, led by controlled provisions. However, business trends remain modest, impacted by continued deleveraging by corporates. The bank has been able to maintain a strong control on restructured assets at 1.2% of loans, while the SMA pool has declined sharply,” the brokerage has said.

Current market price Rs 710
Target price Rs 860
Gains 21.00%

Motilal Oswal sees a potential upside of almost 21% on the stock of Bharti Airtel from the current levels.

According to Motilal Oswal, the management is making the right noise in terms of steady market share gains, premiumization, cross selling through digital initiatives, and healthy inroads in non-Mobile revenue streams like payments bank, Home, and Enterprise segments. It expects 20% consolidated EBITDA CAGR over FY21-23E, along with tariff/consolidation to drive FCF/deleveraging.

“Bharti’s superior execution quality is reflected in its strong performance in the last 8-10 quarters; 25% YoY growth in consolidated EBITDA, despite no tariff

hikes; and consistent subscriber and revenue market share gains,” the brokerage has said.

Buy Bharti Airtel with a price target of Rs 875

Buy Bharti Airtel with a price target of Rs 875

Motilal Oswal sees a potential for a re-rating in both the India and Africa businesses on the back of steady earnings growth.

“We value Bharti Airtel on a Sep’22E basis, assigning an EV/EBITDA of 11x/5x to the India Mobile/Africa business, arriving at an SoTP-based target price of Rs 860. Our estimates do not factor in any upside from a tariff hike or steep market share gains from VIL’s financial stress. We maintain our Buy rating,” the brokerage has said.

Disclaimer

Disclaimer

The above stock has been picked from the brokerage report of Motilal Oswal. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

1 Financial, 1 Healthcare Stocks To “BUY” As Recommended By Motilal Oswal

[ad_1]

Read More/Less


Buy Divi’s Laboratories at a target price of Rs 6,050

The brokerage believes the stock of Divi’s Laboratories may appreciate up to a target price of Rs 6,050 from current levels, and forecasts gains of +16 percent. The stock was recommended at Rs 5,205 by the brokerage, but it is today trading at Rs 4,812. According to the brokerage, DIVI’s revenue grew 14% YoY to INR19.9b (est. INR20.4b), and the gross margin remained flat YoY at 67.1%. EBITDA margin contracted by 180bp YoY to 41.5% (est. 42.7%) due to higher other expenses/employee costs (up 150bp/30bp as a percentage of sales).

“DIVI’s EBITDA rose 9% YoY to INR8.3b (est. INR8.7b) and PAT grew at a higher rate (15% YoY) to INR6.1b (est. INR6b) due to a lower tax rate of 20.2% in 2QFY22 (v/s 25.1% in 2QFY21)” said the brokerage. According to the research report of Motilal Oswal “inventories of DIVI’s stood at INR 26.8b at the end of 1HFY22 v/s INR17b/INR21.5b at the end of 1H/FY21.”

According to Motilal Oswal, the management stated that “DIVI has recorded some sales of Molnupiravir in 2QFY22. The management said it may not incur further CAPEX on this product in the near term as it has built sufficient capacity to cater to upcoming demand for this drug. The company has started manufacturing Molnupiravir API across all three production lines. The Generics-to-CS sales split stood at 46:54 in 1HFY22. Sales of Nutraceuticals stood at INR1.6b/INR3.1b in 2Q/1HFY22.”

“We reduce our FY22E/FY23E EPS estimate by 5%/2% to reflect some slowdown in offtake related to the Generics segment and higher operational costs”, said the brokerage. Motilal Oswal has said, “We expect a 34% earnings CAGR over FY21-23E, led by increased business prospects from CS and Generics, benefits from Molnupiravir supply to the innovator, improved growth in Nutraceuticals, new product additions in the Generics segment, as well as ~240bp margin expansion on process and productivity improvements.” The broking house has also reported that “Our TP stands at INR6,050 based on 36x 12-month forward earnings. We remain positive on DIVI on the back of strong demand in the CS segment, reduced cost of production due to backward integration, and the Kakinada project being back on track. We reiterate our Buy rating.”

Buy IndusInd Bank at a target price of Rs 1400

Buy IndusInd Bank at a target price of Rs 1400

The brokerage expects IndusInd Bank’s shares to rise to a target price of Rs 1400 from current levels, implying gains of 18 percent. The brokerage recommended the stock to buy at a market price of Rs 1,189, but it is now trading at Rs 1,063.65.

According to the brokerage “The impact of COVID-19 on asset quality appears to be controlled as asset quality ratios witnessed an improvement, with GNPA/NNPA at 2.8%/0.8% as of 2QFY22. Collection efficiency improved to 98% in Sep’21. We expect this to gain further traction. The restructuring book remains high at ~3.6% v/s peers. However, healthy PCR (~72%), coupled with a provision buffer of 1.4% of loans, provides comfort. We remain watchful of asset quality as slippages could remain elevated in the near term and moderate post FY22. We estimate credit cost to remain at 2.8%/2.0% in FY22E/FY23E and moderate to 1.8% in FY24E.” The brokerage has said “IndusInd Bank had rolled out its ‘Planning Cycle 5′ (CY20-23), wherein it would focus on fortifying its liabilities, scaling up its key focus businesses, and investing in new growth engines. It expects the loan book to grow at 15-18% over FY2-223E (unsecured retail at less than 5%), with the CASA ratio in excess of 40% by FY23E. We estimate the loan book to grow 17% over FY21-24E.”

According to Motilal Oswal, “the management has maintained its loan growth and credit cost guidance as given during the 2QFY22 results. It expects loan growth to be 16-18% and credit cost of 160-190bp, plus an additional 50bp for Vodafone. Thus, the total credit cost guidance stands at 240bp. We estimate a loan growth CAGR of 17% over FY21-24E / credit cost of 2.8% for FY22E and moderate it to 2.0%/1.8% for FY23E/FY24E.”

Motilal Oswal in its research report said “The stock could witness some pressure due to adverse media articles and asset quality stress reported by some other MFI lenders. Nevertheless, we expect the impact to be controlled. We expect RoA/RoE of 1.8%/15.1% in FY23E. We maintain BUY, with unchanged TP of INR1,400 (1.9x 1HFY24E ABV).”

Disclaimer

Disclaimer

The above stocks have been picked from the brokerage report of Motilal Oswal. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

Buy This Company Stock With 24% Return In 1 Year: ICICI Securities

[ad_1]

Read More/Less


Target Price

The current market price of Graphite India (GIL) is Rs. 525. ICICI Securities has set a target price of Rs. 650 for the stock that is expected to give 24% returns in a 1 year period to investors. So investors can consider this stock to buy now.

Stock expectation
Current market price Rs. 525
Target price Rs. 650
1 year returns 24.00%

Company performance

Company performance

Graphite India reports a consolidated capacity utilization of 81% compared to 60% in Q2FY21 and 75% in Q1FY22. ICICI Securities estimate for the company was 78%. the company’s consolidated topline for the quarter stood at Rs. 692 crore, up 43% YoY and 13% QoQ. The brokerage firm expected it to be Rs. 712 crore.

Graphite India reports a consolidated net profit during the last quarter at Rs. 128 crore, which was down 15% QoQ. On the other hand, they reported a consolidated EBITDA at Rs. 109 crore, which was down 23% QoQ. However, their consolidated EBITDA margin came in at 15.8% compared to 23.1% in Q1FY22

ICICI Securities' stand on the stock

ICICI Securities’ stand on the stock

The brokerage firm in their report said, “GIL’s share price has grown by ~3x over the last 12 months (from ~ Rs. 176 on November 2020 to ~ Rs. 525 levels in November 2021). We maintain our BUY rating on the stock. We value GIL at Rs. 650, 6.5x FY23E EV/EBITDA. The performance set to improve, going forward.” Hence, keeping a target of Rs. 650, investors can buy this stock, as recommended by ICICI Securities.

About Graphite India (GIL)

About Graphite India (GIL)

ICICI Securities has said that Graphite India (GIL) is the largest Indian producer of graphite electrodes by total capacity. The company’s manufacturing capacity of 98000 tonnes PA is spread over 3 plants at Durgapur & Nashik in India & Nuremberg in Germany. “GIL manufactures a full range of graphite electrodes, it stays focused on the higher-margin, large diameter, ultra-high power (UHP) electrodes. GIL has over 40 years of technical expertise in the industry”, the firm informed.

Disclaimer

Disclaimer

The above stock has been picked from the brokerage report of ICICI Securities. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution. Greynium Information Technologies, the author, and the brokerage house are not liable for any losses caused as a result of decisions based on the article.



[ad_2]

CLICK HERE TO APPLY

5 Multibagger Penny Stocks Of 2021 That Delivered Up To 1800% Return So Far

[ad_1]

Read More/Less


1. JITF Infralogistics:

The company commands a market cap of Rs. 575 crore and has recorded a surge of 3073 percent in the last one year. While YTD returns have also been phenomenal of over 1700 percent. The exorbitant price rise in the stock is being attributed to low liquidity in the stock. The other concern with the company is institutional holding in the company is by investors who were recently under the scanner owing to investment in Adani Group firms.

In the previous quarter ending June 2021, the company posted a net loss of Rs. 0.04 crore. The company’s stock was locked in upper circuit from August to October 2021.

The company works in the area of water, wastewater and solid waste management, logistics and transportation equipment fabrication.

2.	ANG Lifesciences:

2. ANG Lifesciences:

The pharma company has returned a staggering 2896 percent return in the last 1-year, while YTD return have been over 1812%. After acquiring 2 formulation manufacturing facilities, the company’s stock is on the run. Also, the company declared a bonus in the ratio of 1:1 which is also providing a stock the current fillip as the investors lap up stocks for which record date has been declared.

Incorporated in the year 2008, the company has its focus primarily on Dry Powder Injectables (SVP). ANG Lifescience is committed to Quality products and services that address the prevention , diagnosis and treatment of diseases, thus enhancing people’s health and quality of life .

3. Orchid Pharma:

3. Orchid Pharma:

The pharma company over a 1-year period has risen 1890 percent and last quotes at a price of Rs. 413 per share on the NSE.

The was relisted in 2020 at a price of Rs. 18 and since then till April of this year gave an over 14000 percent return. Limited stock or free float is the main reason spurring the stock price of Orchid.

Established in 1992 as an export-oriented unit (EOU), Orchid Pharma Ltd. (Orchid) is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing.

Orchid Pharma last commands an market cap of Rs. 1685 crore.The stock’s 52-week high price is Rs. 2654.

4.	3i Infotech:

4. 3i Infotech:

The computer software firm was relisted and since then has been in high demand after the company’s debt restructuring plan. As a result of the new plan, the company’s capital base has been brought down. The stock is expected to see further upside. The company is now a debt free enterprise.

Over the year gone by, shares of the company have gained 1,468%.

5.	Authum Investment

5. Authum Investment

Authum Investment & Infrastructure is a registered NBFC, carrying on the business of investment in shares & securities and also, financing activities. The company has been in news after it came out as the successful bidder for the acquisition of Reliance Commercial Finance (RCF) and Reliance Home Finance. Authum will pay around Rs 22 bn for RCF and close to Rs 29 bn for Reliance Home Finance.

Stocks YTD return 1 year return Sector
ANG Lifesciences 1812% 2896% Pharma
Authum Investment 714% 940% NBFC
JITF Infralogistics >1700% 3073% Diversified
Orchid Pharma 1890% Pharma
3i Infotech 715.5% 1683% Software

Disclaimer:

Disclaimer:

The story above just highlights the mind boggling returns these penny stocks managed to gave, nonetheless it is not a recommendation to buy in these shares as these stocks in particular are highly risky and past returns are no metric to decide on an investment.

GoodReturns.in



[ad_2]

CLICK HERE TO APPLY

PNB Housing chief on Carlyle deal pull-out, BFSI News, ET BFSI

[ad_1]

Read More/Less


Pulling out from the Rs 4,000-crore Carlyle-led deal was a conscious choice of PNB Housing Finance as the company did not want to entangle in a protracted legal battle and lose focus on the lending business, its Managing Director and CEO Hardayal Prasad said.

Last month, the company said it has decided not to proceed with the Rs 4,000-crore capital infusion deal led by Carlyle as a legal battle will not be in the best interests of the company and its stakeholders.

The deal was finalised on May 31. Soon after, it mired into a controversy with regards to the valuation of the shares being offered to the investors. Subsequently, the matter reached the Securities Appellate Tribunal (SAT) after the intervention of markets regulator Sebi.

“If you look at it, there is nothing that we did wrong. We followed the policy of the Sebi, the LODR instructions, we tried to do everything. It was only a question of interpretation.

“But, it was looking like a long-drawn process due to hurdles in legal approvals,” Prasad told PTI in an interview.

He said the split verdict of the SAT also proves that it was a matter of interpretation only as the company’s contention was vindicated by one of the judges in the matter, reiterating: “I don’t think we did anything wrong”.

Prasad added that one of the judges, the presiding officer, gave the judgment in the company’s favour. “But, we are very clear that we don’t want any protracted legal battle. We want to concentrate on our work and go ahead.”

He said a significant amount of bandwidth is utilised when you are going to do it and it would have been a slightly long-protected legal battle.

“I am not in that business, we are in the business of lending, in the business of financing. What is the point in remaining distracted by these kinds of things. So, we decided that okay they are the regulator and we decided to go ahead with the pull-back (from the deal),” Prasad said.

After the split verdict of the SAT in August, Sebi had approached the Supreme Court. However, the apex court dismissed Sebi’s appeal in late October as it became infructuous when PNB Housing Finance said it will pull out from the deal.

The company has filed an application to withdraw its appeal to the Securities Appellate Tribunal.

Prasad said the company is much in the need of the desired capital and it will look for all the venues to raise money, be it through borrowings, qualified institutional placement (QIP), rights issues or preference issues.

“Whether we do it through borrowings or QIP, preferential issue, rights issue, any other things that we can do, we are keeping everything open and we will see to it and at the right time, we will approach the board to permit us to raise the money,” Prasad said.

He added that the company will continue to look for opportunities.

“We remain engaged with everybody. See how we can move forward in terms of capital raising. We require to raise the capital, despite a solid capital adequacy ratio, and the gearing position.

“But, we would still like to raise capital to enable us to grow even faster than we are growing,” he said.

Right now, all stakeholders of the company remain supportive of the company. They know that the capital is required, they know that the company has a great, bright future, Prasad added.

They have also seen that in the past nine quarters, there has been a slow and steady movement on a lot of fronts.

“So, we would do it, since they are all supportive and they understand that the company requires it. We will look at all options that are there in terms of raising the money,” Prasad said.

State-owned Punjab National Bank (PNB) is the company’s promoter with a 32.6 per cent holding in the company.

On being asked what was PNB’s opinion on pulling out from the deal, he said: “We explained to them that this is the reason and we would like to pull back from the deal. Because of the protracted legal nature, it is not taking us anywhere and it is distracting the overall focus of the business.”

All of them agreed that this is the right thing to do, Prasad added.

In the second quarter ended September 2021, the company posted a net profit of Rs 235 crore, down by 25 per cent from a year ago, mainly on account of a fall in interest income and higher provisioning for bad loans.



[ad_2]

CLICK HERE TO APPLY

Multibagger Stocks: These Stocks Rose Over 2000% And Up To 4000% In This Year

[ad_1]

Read More/Less


Chennai Ferrous Industries

The company has enough cash on hand to cover its contingent liabilities. The stock returned 2763.71 percent over three years, compared to 74.57 percent for the Nifty Smallcap 100. The company’s yearly revenue growth rate of 471.59 percent outpaced its three-year compound annual growth rate of 51.58 percent.

For the past three years, the company has shown a good profit growth of 48.44 percent and the company has grown its revenue by 34.73 percent.

The company’s debt has been reduced by 32.06 crores. The company has had poor ROE for 3 years.

With a healthy interest coverage ratio of 414.02, the company is in good shape.

Gita Renewable Energy

Gita Renewable Energy

Since the last five years, the company has had no debt. In the fiscal year ending March 31, 2021, the company spent less than 1% of its operating revenues on interest charges and 50.42 percent on labour costs. For the past three years, the company has posted a negative return on investment (ROI). Gita Renewable Energy Ltd., founded in 2010, is a Small Cap business in the Miscellaneous category with a market capitalization of Rs 85.37 crore.

TTI Enterprise

TTI Enterprise

Since the last five years, the company has had no debt. The company’s yearly revenue growth rate of 433.61% surpassed its three-year CAGR of 48.12%. TTI Enterprise Ltd., founded in 1981, is a Small Cap business in the Financial Services industry with a market capitalization of Rs 96.54 crore. Over the last three years, the company has generated dismal Operating Income growth of -29.34 percent. Provisioning and contingencies have risen by 361.54%.

The company is registered as a non-banking financial company with the RBI (NBFC). The business of investing in shares and securities, as well as providing short- and long-term financing, has long been the focus of the company.

National Standard (India)

National Standard (India)

The company’s annual sales increase of 111.24 percent surpassed its three-year compound annual growth rate (CAGR) of -12.95 percent. The company spent Rs 3.25 crore on investing operations, a rise of 451.46% year on year. National Standard (India) Ltd., founded in 1962, is a Small Cap firm in the Engineering sector with a market capitalization of Rs 25,343.90 crore.

JITF Infralogistics

JITF Infralogistics

Jindal ITF is altering established norms in the areas of water, wastewater, and solid waste management, as well as logistics and transportation equipment fabrication. Jindal ITF is involved in establishing a strong basis for a secure and sustainable future through its subsidiaries. The stock returned 1059.33 percent over three years, compared to 74.57 percent for the Nifty Smallcap 100. For the fourth quarter in a row, the company has lost Rs 40.62 crore. Stock returned 1059.33 percent over three years, compared to 74.57 percent for the Nifty Smallcap 100.

Multibagger Stocks: These Stocks Rose Over 2000% And Up To 4000% In This Year

Multibagger Stocks: These Stocks Rose Over 2000% And Up To 4000% In This Year

Company Latest price in Rs Sector Returns in 2021
Chennai Ferrous Industries 174.40 Iron & Steel 4,406.46%
Gita Renewable Energy 207.60 Power 2,861.48%
TTI Enterprise 37.00 Finance 2,681.95%
National Standard 12,671.95 Iron & Steel 2,625.15%
JITF Infralogistics 225 Logistics 1,657.81%

Disclaimer

Disclaimer

Investing in stocks has the risk of financial loss. As a result, investors must proceed with prudence. Greynium Information Technologies and the author are not accountable for any damages incurred as a result of decisions based on the article. Please keep in mind that past performance does not guarantee future results.



[ad_2]

CLICK HERE TO APPLY

How strong is the economic recovery? Economists go the extra mile to find out, BFSI News, ET BFSI

[ad_1]

Read More/Less


Economists are tracking proxy economic indicators such as footwear sales, city billboard usage, product and services advertisements, travel-related searches, fish, meat and poultry purchases, and demand for smartphones to gauge the strength of the post-pandemic recovery.

A string of high-frequency alternative indicators, along with government-issued data sets such as goods and services tax (GST) collection, foreign trade, e-way bills and Purchasing Managers’ Index (PMI), have shown the economy has gathered pace. But gauging the true extent of recovery is proving difficult, given the distortion caused by the extreme base effect of Covid-hit FY21.

The proxy indicators are helping reduce the noise. Most of these indicators suggest strong economic momentum.

Footwear maker Bata booked a net profit of Rs 37 crore in the September quarter on the back of higher sales across retail outlets and digital channels, swinging back to profitability after a loss in the previous financial year.

Higher footwear sales are a proxy for, or an alternative lead indicator of, the “confidence level” among consumers. More footwear sold means people have started going out after several months of Covid-led lockdowns and restrictions.

“Reduction in Covid cases and wide vaccination coverage have led to an increase in consumer confidence and morale,” said Gunjan Shah, CEO, Bata India.

“People are gradually moving towards normalcy… this is resulting in increased footfall across all our outlets.”

“These proxy indicators may not be accurate all the time, but they can give you a direction as to where the country is headed,” said Devendra Kumar Pant, chief economist, India Ratings.

Sachchidanand Shukla, chief economist at Mahindra Group, who tracks 37 variables to gauge consumption patterns across the country, said the recovery in the services sector is helping growth. Key metrics such as loan collection data, tractors, farmers’ income and consumer durables are gaining traction, he said.

“If there’s no third wave, and Covid cases hit a declining trend with wide vaccination coverage, we may see double-digit economic growth this year,” said Shukla. “Farmers’ cash flows are better, as there have been higher levels of government-led procurement this year.” The services PMI touched a decade high in October.

Madan Sabnavis, chief economist at CARE Ratings, said there is a marked improvement in recovery since the Ganpati festival. In the run-up to Diwali, there has been a voluminous increase in the number of companies booking advertisements for their products and services, he said.

“We’ll have to see if the higher levels of GST collection can be maintained post the festival season… But, as of now, things are looking up. Even bank credit is showing signs of recovery,” said Sabnavis. G Chokkalingam, managing director at Equinomics Research, said most high-frequency indicators – such as diesel sales, truck and rail freight rates, spatial distribution of monsoon, water storage levels in reservoirs, life insurance premiums and domestic pharmaceutical formulation sales– are showing an upward trend.

“There’s liquidity in the system for now, thanks to the stimulus packages given by governments the world over. Even the FDI (foreign direct investment) flow to India is stable now,” said Chokkalingam. “Systemic liquidity will keep the asset classes buoyant for some more time.”

Abheek Barua, chief economist at HDFC Bank, said the sales of fish, meat and poultry – the “protein basket”– hovered at elevated levels over the past few weeks, denoting stability in rural household incomes. But this cannot be a surefire indicator this time round, he said, as the supply of poultry has been severely hit after a cull due to avian flu.

“We are seeing signs of a switch from cereals and pulses to fish and meat currently, but this may not be an apt indicator now. Instead, we are looking at smartphone sales in rural India,” said Barua.

“There’s strong recovery, but it is biased towards the organised sector and mid-to high-income earners, and is now restricted to urban pockets. There could be stress among MSMEs (micro, small and medium enterprises) and low-income households.”

Consulting firm Counterpoint Research said smartphone shipments maintained strong momentum after the second Covid-19 wave, as high consumer demand outweighed supply. The sub-Rs 20,000 phone category has seen brisk sales in recent months, it said in a report.

QuantEco Research economist Yuvika Singhal, who tracks Google and Apple mobility data along with other high-frequency indicators, said, “The mobility data points show that more people have started visiting transit stations – denoting long-distance travel. We are also seeing mobility towards workplaces now.”

Singhal further said, “For the services sector, we use Google searches as one of the proxies. More people are searching for flight tickets, holidays, consumer durables and even movie tickets now. Almost all city-based billboards are flashing advertisements now… for sure, the pace of recovery has continued for five months. We’ll have to see if it continues.”



[ad_2]

CLICK HERE TO APPLY

Rupee to gain strength on likely return of FIIs, BFSI News, ET BFSI

[ad_1]

Read More/Less


Mumbai, The expected return of foreign capital into India’s key indices will strengthen the Indian rupee further during the upcoming week.

Accordingly, the rupee is likely to touch the 74 to a USD mark during this period.

The FIIs have been on a selling spree in India’s equity market, however, the rate of off-load has significantly come down during the last few sessions.

On last Thursday, during the hour-long ‘Muhurat Trade Session’, FIIs sold just Rs 328.11 crore worth of stocks on the BSE, NSE and MSEI in the capital market segment.

“Rupee closed strong in this short trade week at 74.50 to a USD on back of lower crude and IPO inflows. Also on the back of IMF’s suggestion of lower interventions to India’s Central bank,” said Sajal Gupta, Head, Forex and Rates at Edelweiss Securities.

“The US yields also softened a bit after touching 1.70 levels paving way for a rally in risk assets. Rupee is expected to test 74 levels this week and the Nifty is likely to gain further strength.”

According to Devarsh Vakil, Deputy Head of Retail Research, HDFC Securities: “This week rupee behaved exactly as expected and appreciated amid heavy FPI flows from ongoing IPOs. Better PMI numbers of manufacturing and service activities indicating economic conditions are improving.”

“We now expect the Rupee to consolidate its recent gains and also factor in the important announcement of tapering from the US FOMC this week. We continue to remain rupee bulls, and we expect it to appreciate towards the 73.5-mark over the course of the next few weeks.”

On the other hand, Gaurang Somaiya, Forex & Bullion Analyst, Motilal Oswal Financial Services said: “Domestic factors continue to be in favour of the rupee as a number of IPOs are attracting fund flows and thereby supporting the currency. Inflation and industrial production too will be in focus on the domestic front.”

“Rise in inflation is likely to trigger volatility for the currency as well as 10-year yields. We expect the momentum for the rupee would continue to remain positive and it could quote in the range of 74.20 and 75.20.”

In addition, the currency desk of Emkay Global Financial Services: “This week was a short week with USDINR spot witnessing a downtrend on IPO subscriptions.”

“But we can brace for a heightened volatility next week after the FOMC, BOE monetary policy decisions, OPEC meeting and US NFP data.”



[ad_2]

CLICK HERE TO APPLY

1 39 40 41 42 43 387